Neurocrine Biosciences (NBIX) reported a net loss of $24.0 million, or $0.28 loss per share, compared to a net loss of $13.4 million, or $0.18 loss per share, for the same period in 2014. For the six months ended June 30, 2015, the Company reported a net loss of $25.2… Read More

Neurocrine Biosciences (NBIX) reported a net loss of $24.0 million, or $0.28 loss per share, compared to a net loss of $13.4 million, or $0.18 loss per share, for the same period in 2014. For the six months ended June 30, 2015, the Company reported a net loss of $25.2… Read More

[from the Portfolio Update in today’s issue of Smart Tech Investor]I am adding Dyax Corp. (DYAX) to the STI Medical Profits Portfolio because it is very close to having a real shot for FDA approval for a drug (DX-2390) that treats  Hereditary Angioedema, a genetic disorder that occurs in… Read More

[from the Portfolio Update in today’s issue of Smart Tech Investor]I am adding Dyax Corp. (DYAX) to the STI Medical Profits Portfolio because it is very close to having a real shot for FDA approval for a drug (DX-2390) that treats  Hereditary Angioedema, a genetic disorder that occurs in… Read More

[from today’s Portfolio Update in Smart Tech Investor]I am adding Tableau Software (DATA) to the Next Wave Portfolio because it’s one of the key beneficiaries of the shifting BI market. Tableau’s analytics software for data visualization is increasingly being implemented across all sizes of organizations. The company’s customer… Read More

[from today’s Portfolio Update in Smart Tech Investor]I am adding Tableau Software (DATA) to the Next Wave Portfolio because it’s one of the key beneficiaries of the shifting BI market. Tableau’s analytics software for data visualization is increasingly being implemented across all sizes of organizations. The company’s customer… Read More

Our EBIS portfolio triggered some sell stops this past week.  Repligen and Bio-Rad have been removed from the STI Medical Profits portfolio.  However, due to some potential pricing issues in the Flash Crash on 8/24/15 some of the pricing may or may not have been accurate.  Thus, we are not removing Neurocrine Biosciences… Read More

Our EBIS portfolio triggered some sell stops this past week.  Repligen and Bio-Rad have been removed from the STI Medical Profits portfolio.  However, due to some potential pricing issues in the Flash Crash on 8/24/15 some of the pricing may or may not have been accurate.  Thus, we are not removing Neurocrine Biosciences… Read More

As explained in today’s edition of Smart Tech 50 Weekly Movers, we are selling Oracle (ORCL) and Intel (INTC) out of the STI Investments Portfolio now that they have closed beneath their stop prices and carry a Smart Tech Rating score less than the sector average. We are… Read More

As explained in today’s edition of Smart Tech 50 Weekly Movers, we are selling Oracle (ORCL) and Intel (INTC) out of the STI Investments Portfolio now that they have closed beneath their stop prices and carry a Smart Tech Rating score less than the sector average. We are… Read More